p53
Illumina, Kartos Therapeutics Partner to Develop TP53 Companion Diagnostic
The two companies will codevelop the next-generation sequencing test for Kartos's MDM2 inhibitor, KRT-232, being studied in TP53 wild-type blood cancers.
Roche Elecsys Anti-p53 Test for Cancer Diagnosis Earns CE Mark
The immunoassay can be used to monitor cancer cell remnants in a patient's body and help determine which patients need less invasive treatment.